Harm R Haak
Overview
Explore the profile of Harm R Haak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Appelboom Y, Groenen Y, Notten D, De Bruin A, Buijs J, Haak H, et al.
PLoS One
. 2025 Jan;
20(1):e0314052.
PMID: 39820942
Background And Importance: The emergency department (ED) is a hectic place, where many critically ill patients are treated. For residents working in the ED, this environment may be demanding. Objectives:...
2.
Debets P, Dreijerink K, Engelsman A, Dahele M, Haak H, Steenaard R, et al.
Eur J Cancer
. 2024 Nov;
213:115123.
PMID: 39550299
No abstract available.
3.
Reinders E, de Vries R, Wouters-van Poppel P, Van Riel N, Haak H
Diabetes Res Clin Pract
. 2024 Aug;
216:111833.
PMID: 39179114
The global rise in diabetes prevalence poses a significant challenge to healthcare providers, stimulating interest in digital interventions such as educational games. However, the impact and availability of research-developed diabetes...
4.
Weijers J, Prins M, van Dam D, Van Nieuwkoop C, Alsma J, Haak H, et al.
Telemed J E Health
. 2024 Jun;
30(10):2563-2572.
PMID: 38938204
To determine patients' perspectives on home monitoring at emergency department (ED) presentation and shortly after admission and compare these with their physicians' perspectives. Forty Dutch hospitals participated in this prospective...
5.
Debets P, Dreijerink K, Engelsman A, Dahele M, Haak H, Steenaard R, et al.
Eur J Cancer
. 2024 Mar;
202:114035.
PMID: 38554541
No abstract available.
6.
Riedmeier M, Antonini S, Brandalise S, Costa T, Daiggi C, de Figueiredo B, et al.
Eur J Endocrinol
. 2024 Mar;
190(4):G15-G24.
PMID: 38552173
Objective: Mitotane is an important cornerstone in the treatment of pediatric adrenal cortical tumors (pACC), but experience with the drug in the pediatric age group is still limited and current...
7.
Debets P, Dreijerink K, Engelsman A, Dahele M, Haak H, Steenaard R, et al.
Eur J Cancer
. 2023 Nov;
196:113424.
PMID: 37977106
Introduction: Historically, stage IV adrenocortical carcinoma (mACC) has a poor prognosis with a median overall survival (OS) of only 5 months. Based on the FIRM-ACT trial published in 2012, guidelines...
8.
Steenaard R, Feelders R, Dogan F, Van Koetsveld P, Creemers S, Ettaieb M, et al.
Biomedicines
. 2023 Jul;
11(7).
PMID: 37509652
The differentiation between benign and malignant adrenocortical tumors based on pathological assessment can be difficult. We present a series of 17 patients with unclear malignant tumors, of whom six had...
9.
van der Velde M, van der Aa M, van Daal M, Kremers M, Keijsers C, van Kuijk S, et al.
BMC Geriatr
. 2022 Jul;
22(1):584.
PMID: 35840904
Background: A variety of prediction models concerning COVID-19 have been proposed since onset of the pandemic, but to this date no gold standard exists. Mortality rates show a sharp increase...
10.
Berends A, Bolhuis M, Nolte I, Buitenwerf E, Links T, Timmers H, et al.
Biomedicines
. 2022 Apr;
10(4).
PMID: 35453646
Background: Presurgical treatment with an α-adrenergic receptor blocker is recommended to antagonize the catecholamine-induced α-adrenergic receptor mediated vasoconstriction in patients with pheochromocytoma or sympathetic paraganglioma (PPGL). There is, however, a...